文献速递头颈部肿瘤放疗放疗物理与技术

鼻咽癌耳蜗保护优化放疗研究

Cochlea sparing optimized radiotherapy for nasopharyngeal carcinoma.
PubMed 文献 · Radiat Oncol · 2021-04-01

本研究对20例接受根治性放化疗的鼻咽癌患者(6例IMRT、14例VMAT)在原QUANTEC约束基础上重新优化计划,采用VMAT(2-2.5弧)进一步保护耳蜗。结果显示双耳蜗中位剂量显著降低,且不影响靶区覆盖和其他计划质量参数,耳鸣与听力损失的NTCP亦显著改善。

要点

  • VMAT再优化可显著降低双耳蜗中位剂量,且不牺牲PTV覆盖。
  • 再优化后耳鸣与听力损失NTCP均显著下降。
  • QUANTEC耳蜗约束之外仍有进一步保护空间。

核心结论

  • 在VMAT治疗的鼻咽癌患者中,超越现行QUANTEC约束的耳蜗保护显著改善且不影响PTV剂量覆盖。
  • 鉴于放化疗后听力毒性似乎无明确阈值,未来治疗计划应考虑进一步保护耳蜗。

研究设计与样本

  • 研究纳入20例接受根治性放化疗的鼻咽癌患者,其中6例IMRT、14例VMAT,原计划基于QUANTEC危及器官约束。
  • 耳蜗由两名放射肿瘤科医生独立重新勾画,靶区和其他危及器官未改动,原计划以VMAT(2-2.5弧)重新优化,目标为耳蜗平均剂量<45 Gy且不牺牲靶区覆盖。
  • 采用Wilcoxon符号秩检验比较再优化计划与参考计划的差异,p<0.05为显著。

主要发现

  • 再优化计划双耳蜗中位剂量显著低于参考计划:左侧14.97 Gy vs 24.09 Gy,右侧18.47 Gy vs 26.05 Gy,p<0.001。
  • 再优化未损害其他计划质量参数。
  • 暴露最高部位耳鸣的中位NTCP由原计划的11.3%(范围3.52-91.1%)降至再优化计划的4.60%(范围1.46-90.1%),p<0.001。
  • 暴露最高部位听力损失的中位NTCP由0.03%(范围0-99.0%)改善至0.00%(范围0-98.5%),p<0.001。

关键数值与推荐

  • 原计划耳蜗平均剂量目标为<45 Gy。
  • 再优化采用VMAT 2-2.5弧,不牺牲靶区剂量覆盖。
  • 双耳蜗中位剂量:左侧14.97 Gy vs 24.09 Gy,右侧18.47 Gy vs 26.05 Gy,p<0.001。
  • 耳鸣中位NTCP:11.3%(范围3.52-91.1%)vs 4.60%(范围1.46-90.1%),p<0.001。
  • 听力损失中位NTCP:0.03%(范围0-99.0%)vs 0.00%(范围0-98.5%),p<0.001。

临床怎么用

  • 鼻咽癌根治性放化疗VMAT计划可在QUANTEC耳蜗约束基础上进一步优化耳蜗保护。
  • 再优化耳蜗保护不牺牲PTV剂量覆盖和其他计划质量参数。
  • 考虑听力毒性无明确阈值,未来治疗计划应主动纳入更严格的耳蜗保护策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Definitive chemoradiotherapy (CRT) is standard of care for nasopharyngeal carcinoma. Due to the tumor localization and concomitant platinum-based chemotherapy, hearing impairment is a frequent complication, without defined dose-threshold. In this study, we aimed to achieve the maximum possible cochleae sparing. MATERIALS AND METHODS: Treatment plans of 20 patients, treated with CRT (6 IMRT and 14 VMAT) based on the QUANTEC organs-at-risk constraints were investigated. The cochleae were re-delineated independently by two radiation oncologists, whereas target volumes and other organs at risk (OARs) were not changed. The initial plans, aiming to a mean cochlea dose < 45 Gy, were re-optimized with VMAT, using 2-2.5 arcs without compromising the dose coverage of the target volume. Mean cochlea dose, PTV coverage, Homogeneity Index, Conformity Index and dose to other OAR were compared to the reference plans. Wilcoxon signed-rank test was used to evaluate differences, a p value < 0.05 was considered significant. RESULTS: The re-optimized plans achieved a statistically significant lower dose for both cochleae (median dose for left and right 14.97 Gy and 18.47 Gy vs. 24.09 Gy and 26.05 Gy respectively, p < 0.001) compared to the reference plans, without compromising other plan quality parameters. The median NTCP for tinnitus of the most exposed sites was 11.3% (range 3.52-91.1%) for the original plans, compared to 4.60% (range 1.46-90.1%) for the re-optimized plans (p < 0.001). For hearing loss, the median NTCP of the most exposed sites could be improved from 0.03% (range 0-99.0%) to 0.00% (range 0-98.5%, p < 0.001). CONCLUSIONS: A significantly improved cochlea sparing beyond current QUANTEC constraints is feasible without compromising the PTV dose coverage in nasopharyngeal carcinoma patients treated with VMAT. As there appears to be no threshold for hearing toxicity after CRT, this should be considered for future treatment planning.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Lamaj E, Vu E, van Timmeren JE, et al. Cochlea sparing optimized radiotherapy for nasopharyngeal carcinoma. Radiat Oncol. 2021. PMID: 33794949. doi:10.1186/s13014-021-01796-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。